Research programme: inflammatory diseases - Digital Gene Technologies
Latest Information Update: 14 May 2008
At a glance
- Originator Digital Gene Technologies
- Developer Amgen; Digital Gene Technologies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 14 May 2008 Discontinued - Preclinical for Inflammatory bowel disease in USA (unspecified route)
- 12 Aug 2002 Preclinical trials in Inflammatory bowel disease in USA (unspecified route)